Drug Profile
VP1 001
Alternative Names: Compound 29 - Visus TherapeuticsLatest Information Update: 30 Sep 2022
Price :
$50
*
At a glance
- Originator University of California at San Francisco; University of Michigan; University of Washington
- Developer University of California at San Francisco; University of Michigan; University of Washington; Visus Therapeutics
- Class Small molecules; Sterols
- Mechanism of Action Amyloid inhibitors; Protein aggregation inhibitors; Protein folding inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cataracts; Presbyopia
Most Recent Events
- 28 Sep 2022 ViewPoint Therapeutics has been acquired and merged into Visus Therapeutics
- 28 Jun 2020 No recent reports of development identified for research development in Presbyopia in USA (Ophthalmic, Drops)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cataracts in USA (Ophthalmic, Drops)